Skip to main content
U.S. flag

An official website of the United States government

OSBR Showcase Categories

Therapeutics

The NIA Small Business Programs support small businesses who aim to develop therapeutic interventions that address factors that impact the aging population, as well as related conditions like Alzheimer’s disease and related dementias.

The small business awardees below were selected by NIH in 2019-2020 to present their groundbreaking technologies and interventions to potential partners and third-party investors at industry showcases.

  • AgeneBio logoRead about AgeneBio, a small business using NIA funding to develop a novel therapeutic approach that could offer success in the area of Alzheimer’s disease prevention by targeting aberrantly heightened neural activity.

  • Allyx Therapeutics logoRead about Allyx Therapeutics, Inc., a small business using NIA funding to develop an orally bioavailable small molecule that acts as a silent allosteric modulator of metabotropic glutamate receptor 5 in order to slow Alzheimer’s disease progression.

  • AivoCode logoRead about AivoCode, Inc., a small business using NIA funding to develop a therapeutic antibody that neutralizes a novel target, CTGF, which is a hallmark of Alzheimer’s vascular dysfunction and neuroinflammation.

  • Gen-9 logoRead about Artery Therapeutics, Inc., a small business using NIA funding to develop a novel chemical entity CS6253 for the treatment of APOE4-driven dementias, including Alzheimer’s disease.

  • BioPico Systems logoRead about BioPico Systems Inc., a small business using NIA funding to develop “organ-on-a-chip” products (OrganRXTM) that will mimic true human physiology, so that responses to medicines, chemicals, and diseases can be predicted accurately.

  • Calder Biosciences logoRead about Calder Biosciences, a small business using NIA funding to increase the shelf-life of vaccines including the highly contagious respiratory syncytial virus.

  • Cognition Therapeutics logoRead about Cognition Therapeutics, a small business using NIA funding to develop therapeutics for Alzheimer’s disease by blocking the action of toxic oligomers on neurons.

  • The letters D,T, and X written out with Pharma underneathRead about DTx Pharma, a small business using NIA funding to develop therapeutics for Alzheimer’s disease targeting the tau gene/protein, a driver of brain degeneration.

  • General Biophysics logoRead about General Biophysics, a small business using NIA funding to develop a treatment that is expected to lead to slowing Alzheimer’s disease progression and cognitive decline.

  • Juvena logoJuvena Therapeutics, Inc., is a small business using NIA funding to advance a protein therapy for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1), with an orphan drug status and a more than $40 billion total addressable market (TAM).

  • Longeveron written out with Biological Solutions for Aging written underRead about Longeveron, a small business using NIA funding to develop stem-cell therapy for various age-associated diseases and conditions.

  • NeuroEM Therapeutics LogoRead about NeuroEM Therapeutics, a small business using NIA funding to develop and commercialize Transcranial Electromagnetic Treatment as a treatment and possible preventative for Alzheimer’s disease and other neurodegenerative diseases.

  • Neurodon logoRead about Neurodon, LLC, a small business using NIA funding to develop and deliver first-in-class, disease-modifying medicines to patients with diabetes, neurodegeneration, and other life-threatening diseases.

  • Oligomerix logoRead about Oligomerix, a small business using NIA funding to develop therapeutics for the treatment of Alzheimer’s disease by blocking self-association of tau proteins.

  • Three green mountains signifying Ridgeline Therapeutics logoRead about Ridgeline Therapeutics, a small business using NIA funding to further the development of small molecule therapeutics for sarcopenia and hip fracture.

  • SapereBioRead about Sapere Bio, Inc., a small business using NIA funding to develop a pipeline of high-value, lab-developed tests that measure molecular aging signatures.

  • UnderDog Pharma logoRead about Underdog Pharmaceuticals, a small business using NIA funding to develop a treatment that treats damaged cells by targeting extracted oxidized cholesterols with the goal of preventing, treating, and slowing Alzheimer’s disease progression.

nia.nih.gov

An official website of the National Institutes of Health